Drug Infusion Pumps Market Expected to Grow Worldwide Despite Slowing Economy

The world market for Infusion Pumps is expected to reach $3.3 billion by 2010 and $4.5 billion, growing at an average annual rate of 6.2 percent over the 2008 to 2015 period.

Dublin, CA, April 2, 2009 - Marketstrat is pleased announce the release of a new report titled, “Infusion Pumps Worldwide." Despite the recent spate of infusion pump recalls and urgent device alerts, the drug infusion pump market is poised for growth. Increasing rates of aging-related chronic conditions such as cancer, diabetes, neurological conditions, etc. will continue to create a strong demand for drug infusion pumps in the foreseeable future. The downturn in the US economy will slow down new equipment purchases in the US, but revive the rental/ lease market. The weak US dollar will fuel overseas markets, especially in Europe and Asia where refurbished equipment as well as rentals offer new opportunities. Concurrently, concerns over infusion errors due to pump malfunction are driving device manufacturers to redesign their pumps in order to meet the high demand for pumps with improved safety features.

The recent downturn in the US economy and the resulting global impact is not expected to significantly affect the drug infusion pump market. Increasing rates of aging-related chronic conditions such as cancer, diabetes, neurological conditions, etc. will continue to create a strong demand for drug infusion pumps in the foreseeable future. Technological innovations aimed at developing wireless, user-friendly ‘smart pumps’ high-tech safety features such as dose-calculation/ error reduction software (DERS), computerized prescriber order entry (CPOE), alert systems that warn against pump malfunction, blood-glucose monitors for insulin pumps and so on are moving this industry forward.

Infusion pumps are used for administering continuous or long-term medication ranging from anesthesia to pain management and enteral feeding. Infusion therapy is a common drug delivery mechanism for conditions such as diabetes, cancer pain, spasticity, congestive heart failure, etc. It is also the conventional mode of administering anesthesia, blood infusions, etc. in acute care settings. Leading companies in this space is Cardinal Health/ Alaris accounting for 30% of the market. Other leaders are Baxter, Hospira, Medtronic and B. Braun. A recent spate of recalls mostly for pumps from Cardinal Health, Medtronic and Baxter has re-emphasized safety issues and the need for improved design as well as actionable alerts. The largest geographical market is the US accounting for about 50 percent share of the market. However Europe and the emerging Asian markets offer good growth opportunities, particularly for refurbished pumps. Market opportunities in the US lie in the homecare segment, with an increasing demand for ambulatory and PCA pumps.

The US accounts for the largest share of the Infusion Pumps market with large volume infusion pumps being the largest segment after administration sets. Due to the slow economy, the US market for infusion pumps will grow at a slower rate in the upcoming years than previously expected. This will be offset by strong growth of infusion pump markets across Europe and Asia due to decreasing dollar value and corresponding increase in healthcare expenditures. Other rate limiting factors in the US such as reimbursement restrictions are not expected to significantly impact this market. Increasing rates of chronic disease requiring infusion therapy and demand for safer and more advanced infusion technologies will continue to drive this market forward.

Market opportunities for PCA pumps and insulin pumps remain high. PCA pumps allow patients to be in charge of treating their pain. PCA pumps can either be implantable or external devices that are discrete and easy to wear and control. Insulin pumps are available as implantable, syringe pumps and ambulatory pumps. With rates of diabetes rising rapidly around the globe, insulin pumps and other insulin delivery devices are constantly evolving to meet demand. Despite the introduction of non-invasive insulin treatment devices, insulin infusion pumps are still in demand as they become more user-friendly with improved accuracy and built-in blood glucose monitors. Infusion pump technology has been primarily focused on improving medication safety and user-friendly designs to facilitate homecare use. Manufacturers are also aiming to develop closed-loop drug administration systems. The ultimate goal is to allow complete integration of smart pumps with other medical information systems used by clinical facilities.

Smart Pumps or Programmable Pumps and patient-controlled systems (PCA) – allow drug and dosing information to be programmed. An example is the wireless OmniPod Insulin Management System from Insulet Corp. that has a built-in blood glucose monitor. The patient is able to self-administer insulin doses according to blood-glucose levels. The I Pump Pain Management System from Baxter is another example. Wireless Pumps and Software - Wireless pumps that can be operated with a remote control are being adopted by many US hospitals transitioning to high tech health care information systems. Benefits include convenience for staff and more mobility for patients.

The wireless devices have dose-calculation/ error reduction software (DERS) and drug libraries. Integrated monitors allow real-time monitoring of drug administration and initiate alerts to warn of infusion problems, overdosing, etc. Computerized prescriber order entry (CPOE) is another technology that helps in reducing medication errors. Bar-Coded Medication Administration (BCMA) –provides point-of-care verification to ensure the correct patient receives the correct medication. Barcodes on the medication are scanned and matched with the patient's electronic medication administration record or the eMAR. Implantable Pumps, e.g. Baclofen pump, implantable insulin pump. Implantable pumps allow patient to be ambulatory and provide regulated doses for patients needed constant treatment. They are used as a last resort for pain patients who have not had much success with other pain management strategies. Implantable PCAs are also available. Mini or Patch Pumps, e.g. the The Insulin Patch from Medingo which is a convenient, easy to use cost-effective alternative to standard insulin pumps. It is a discreet, patch-like wireless infusion pump. A remote is used to control the pump.

Marketstrat’s 2009 Infusion Pumps report provides market size / revenue estimates and unit shipment forecasts (US $, 2008 – 2015) for infusion pumps by use (Implantable pumps, Syringe pumps, Large Volume, and Ambulatory Infusion Pumps). Data is segmented by country/region for: USA; Canada; Europe; Japan; and the Rest of the World (ROW). Detailed forecasts (Unit Sales, ASP and Revenues) are provided for: Implantable pumps (Constant Flow and Programmable), Syringe pumps (Low-End, High-End), Large Volume (Acute Care, Alternate Care) and Ambulatory Infusion Pumps (Electronic, Non-Electronic, Disposable Pain Control). Also provided are forecasts for Disposables/ Administration Sets, Acute Care and Alternate Care pumps and Rental, Lease, and Purchase/ Sale segments.

For more details on this report please click here.

About Marketstrat, Inc. Marketstrat assists companies with market, technology, and best practice strategies & intelligence, through a unique combination of published reports, solutions, and services. Our strengths include: a deep understanding of the medical devices value chain, state-of-the-art data collection tools, and robust research methodology.

Marketstrat® is a registered trademark of Marketstrat, Inc.

Contact
Sauda Parvatham
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Phone: 925-263-4455